Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Graham

Cancer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancer|July 11, 1992
Critical assessment of prostate cancer stagingS D Graham
Cancer|December 15, 1994
Screening for prostate cancerS D Graham
Cancer|June 15, 1990
Enucleation of tumor versus partial nephrectomy as conservative treatment of renal cell carcinomaR Stephens, S D Graham
Cancer|June 25, 1991
ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-GuerinH Sanders, P McCue, S D Graham
Cancer|February 1, 1997
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinomaM F Townsend, W H Sanders, R O Northway, et al.
Cancer|July 11, 1992
Report of the Committee on Staging and PathologyS D Graham, D G Bostwick, A Hoisaeter, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancer|July 11, 1992
Critical assessment of prostate cancer stagingS D Graham
Cancer|December 15, 1994
Screening for prostate cancerS D Graham
Cancer|June 15, 1990
Enucleation of tumor versus partial nephrectomy as conservative treatment of renal cell carcinomaR Stephens, S D Graham
Cancer|June 25, 1991
ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-GuerinH Sanders, P McCue, S D Graham
Cancer|February 1, 1997
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinomaM F Townsend, W H Sanders, R O Northway, et al.
Cancer|July 11, 1992
Report of the Committee on Staging and PathologyS D Graham, D G Bostwick, A Hoisaeter, et al.
Pageof 1